Is Marker Therapeutics, Inc. overvalued or undervalued?

As of 17 March 2022, the valuation grade for Marker Therapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued given its significant losses and negative returns across multiple periods. The Price to Book Value stands at 1.38, while the EV to Sales ratio is 1.11, indicating a premium relative to its sales despite the lack of profitability. Additionally, the ROE is a staggering -85.09%, reflecting severe inefficiencies in generating returns for shareholders.
In comparison to peers, Marker Therapeutics has a P/E ratio of -0.7992, while ImmunoPrecise Antibodies Ltd. shows a much higher P/E of -13.0409, and HOOKIPA Pharma, Inc. has a P/E of -0.1637, suggesting that Marker is struggling more than its counterparts. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -69.13% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context.